The smoking-cessation drug, reformulated for nasal delivery, could be launched for dry eye, Oyster Point hopes.
The company’s Eysuvis looks set to be approved for dry eye disease, but meeting expectations in this tough market will not be easy.
Heightened Beovu safety concerns could turn into a big problem for Novartis, while rival Regeneron will make the most of any uncertainty.
Roche's Mirros study should prove idasanutlin's worth on top of chemotherapy, while Proqr hopes to Usher in a rare disease cure.
Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.
As Kalvista hopes to attract Merck & Co, Sanofi plays catch-up with Genmab.